Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD, and associated disorders.
Ibogaine, a naturally occurring psychoactive alkaloid, has historically been studied for its potential in treating addiction and other neurological conditions. Silo Pharma's initiative aims to expand its therapeutic applications to TBI, a condition that currently lacks effective pharmacological treatments. The filing of the provisional patent application marks a critical step in protecting the company's intellectual property in this emerging area.
The initiative underscores Silo Pharma's commitment to addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio includes other innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo conducts its research in collaboration with leading universities and laboratories.
Traumatic brain injury is a major public health concern, affecting millions of individuals worldwide annually. Current treatment options are limited, often focusing on symptom management rather than addressing underlying pathophysiology. The potential of ibogaine-based therapeutics to modulate neural pathways involved in TBI and PTSD could represent a significant advancement in the field.
According to the World Health Organization, TBI is a leading cause of death and disability globally, with significant economic and social impacts. The development of targeted therapies by companies like Silo Pharma could address a substantial unmet medical need. The company's decision to explore ibogaine reflects a growing interest in psychedelic and psychoactive compounds for neurological and psychiatric conditions.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. More information is available at silopharma.com.
For the latest news and updates relating to SILO, visit the company’s newsroom at https://ibn.fm/SILO.
